

1 **Virtual High-Throughput Screening of Vapor-Deposited Amphiphilic Polymers for Inhibiting**
2 **Biofilm Formation**

3
4 *Zhihao Feng*^{1†}, *Yifan Cheng*^{1†}, *Alexandra Khlyustova*^{1†}, *Aasim Wani*¹, *Trevor Franklin*¹,
5 *Jeffrey D. Varner*^{1*}, *Andrew L. Hook*^{2*}, *Rong Yang*^{1*}

6
7 ¹ Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University,
8 Ithaca, NY 14853, U.S.A.

9 ² Advanced Materials and Healthcare Technologies, University of Nottingham, Nottingham,
10 NG7 2RD, U.K.

11
12 *Communication authors contact information:

13 Prof. Rong Yang, ryang@cornell.edu

14 Prof. Andrew L. Hook, andrew.hook@nottingham.ac.uk

15 Prof. Jeffrey D. Varner, jdv27@cornell.edu

16 †These authors contributed equally to this work
17

18 **Keywords**

19 Amphiphilic copolymers, high-throughput screening, machine learning, iCVD, antibiofilm
20
21
22
23
24

1 **Abstract**

2 Amphiphilic copolymers (AP) represent a class of novel anti-biofouling materials whose chemistry
3 and composition can be tuned to optimize their performance. However, the enormous chemistry-
4 composition design space associated with AP makes their performance optimization laborious; it
5 is not experimentally feasible to assess and validate all possible AP compositions even with the
6 use of rapid screening methodologies. To address this constraint, we report a robust model
7 development paradigm, yielding a versatile machine learning approach that accurately predicts
8 biofilm formation by *Pseudomonas aeruginosa* on a library of AP. The model excels in extracting
9 underlying patterns in a “pooled” dataset from various experimental sources, thereby expanding
10 the design space accessible to the model to a much larger selection of AP chemistries and
11 compositions. The model is used to screen virtual libraries of AP for identification of best-
12 performing candidates for experimental validation. Initiated chemical vapor deposition (iCVD)
13 was used for the precision synthesis of the model-selected AP chemistries and compositions for
14 validation at solid-liquid interface (often used in conventional antifouling studies), as well as the
15 air-liquid-solid triple interface. Despite the vastly different growth conditions, the model
16 successfully identified the best-performing AP for biofilm inhibition at the triple interface.

17

18

19

20

21

22

23

24

25

26

27

28

29

1 **1. Introduction**

2 Biofilms formed on the surface of indwelling medical devices are the root cause of many life-
3 threatening nosocomial infections.^[1] Compared to their planktonic counterparts, bacteria in these
4 surface-bound biofilm ‘fortresses’ can be up to 1000-fold more resistant to antibiotics and host
5 defenses.^[2] Furthermore, biofilms can facilitate the dissemination of drug resistance genes across
6 multiple co-inhabiting species via horizontal gene transfer.^[3] As such, biofilms further challenge
7 humanity’s capability to stay ahead in the race against emerging bacterial pathogens that already
8 resist multiple last-line antibiotics.^[4]

9 Polymer coatings that inherently resist bacterial attachment and subsequent biofilm formation,
10 namely anti-biofouling coatings, have been brought to the forefront of combating the formation of
11 antibiotic-resistant biofilms. Rather than killing bacteria, as in the case of antibiotics, which
12 inevitably breed resistant strains over time, these novel coatings prevent biofilm by disrupting
13 bacterial adhesion to a solid surface, thus imposing minimal selective pressure on bacteria.^[5,6]
14 Successful examples of such materials include poly(ethylene glycol) brushes,^[7] zwitterionic
15 polymers,^[8] liquid-infused surfaces,^[9] and amphiphilic copolymers (AP).^[10–15] Here, we focus on
16 AP for their capability in mitigating bacterial attachment and biofilm formation at both solid-liquid
17 interfaces and solid-liquid-gas triple interfaces, the latter of which has received far less attention
18 despite their implication in nosocomial material-associated infections.^[12]

19 While the anti-biofouling performance of most polymer coatings has been attributed to
20 hydrophilicity, i.e., the increased enthalpic barrier for foulant adhesion, the fundamental
21 mechanism for AP’s fouling resistance is not well understood. The hypotheses that have received
22 most attention include Baier curve minimum,^[16] dynamic surface reconstruction,^[12,17] and
23 nanoscale or molecular heterogeneity.^[10,14,18,19] Based on these theories, comonomers from the
24 opposite ends of the surface energy spectrum (e.g., pairing of hydrophilic zwitterionic monomers
25 with hydrophobic fluorinated monomers)^[12] have been selected to form AP, which create high
26 surface energy mismatch and thus high thermodynamic penalty upon bacterial contact. Indeed,
27 these AP coatings have demonstrated superior anti-biofilm efficacy than zwitterionic coatings.^[12]

28 Despite their great promise, the discovery of novel and effective AP is limited by the lack of a set
29 of guiding principles, which constitutes a major barrier due to the immense chemistry-composition
30 design space associated with AP. There are countless combinations of hydrophilic and

1 hydrophobic monomer pairs and compositional variations,^[19,20] making a comprehensive
2 assessment extremely laborious. To address that challenge, we resort to data-driven machine
3 learning (ML) models, which have demonstrated considerable potential in predicting biological
4 responses of materials, including biofilm formation.^[21] To generate a sufficiently large dataset for
5 ML models, we adopted a high-throughput screening platform reported by Hook et al., which has
6 been leveraged to discover anti-biofouling copolymers that are unanticipated based on existing
7 theoretical or empirical knowledge.^[6,22] More recently, that platform has enabled the quantitative
8 prediction of the attachment by multiple pathogenic bacteria on a variety of polymers, pointing to
9 the discovery of materials with broad-spectrum efficacy.^[23] However, despite their proven
10 advantage in rapid synthesis and testing, the high-throughput platform relies on solution-phase
11 polymerization, which limits the discovery of AP with high-contrast and molecular-scale
12 heterogeneity. Due to the lack of a common solvent and the tendency for microphase separation
13 for monomer pairs with contrasting surface energies, solution-based synthesis is considered
14 inappropriate to address the detailed molecular design to advance anti-biofouling AP.

15 To enable the precision synthesis of AP using monomer pairs with contrasting surface energies,
16 we leverage an all-dry synthesis approach, namely initiated chemical vapor deposition (iCVD). It
17 has been used for AP synthesis due to its solvent-free nature,^[24,25] a high retention rate of functional
18 moieties borne in the monomers,^[26] and its capability to deposit conformal nanolayers over
19 nanostructured substrates.^[27,28] These unique advantages of iCVD enable the synthesis of desired
20 AP chemistries and their one-step synthesis and application on essentially any substrate while
21 maintaining the beneficial bulk properties (e.g., mechanical properties) and desired surface
22 topographical features (e.g., nanostructures).^[24,29] Despite its many advantages, it is currently
23 challenging to sift through the vast chemistry-composition design space associated with AP using
24 iCVD alone.^[19,20]


25 This begs the question: can we combine the best of both worlds, whereby solution-phase high-
26 throughput synthesis provides a sufficiently large dataset for training a general ML model, which
27 is also applicable to the vapor-deposited AP materials? Moreover, since AP holds great promise
28 in reducing biofilm formation at both solid-liquid interfaces and solid-liquid-air triple interfaces,
29 can a general ML model transfer what is learned from solid-liquid interfaces to complete similar
30 tasks at the triple interfaces?

1 Here, we demonstrate that a general support vector regression (SVR), when trained on a diverse
2 polymer library, captures the fundamental quantitative structure-activity relationship (QSAR)
3 underlying both vapor- and solution-synthesized copolymers, thus allowing transfer of the polymer
4 chemistry-biofilm performance knowledge across polymer synthesis methods. We further
5 demonstrate that transfer is effective even across different growth environments for biofilm
6 formation (i.e., liquid-solid versus triple interface). Compared with the state-of-the-art,^[23] the
7 model reported here expands the accessible number of molecular fingerprints by over twofold, that
8 of monomers by sixfold, and that of unique polymers by over fivefold, while maintaining a desired
9 accuracy of predicting their antibiofilm performance. To demonstrate the potential impact of the
10 model, we show how QSAR can be leveraged to shed light on the structure-performance
11 correlation (by associating low bacterial attachment with specific monomers and molecular
12 fingerprints borne by polymers) and to guide the subsequent synthesis and testing of promising
13 candidates. The model development and implementation procedures demonstrated here can be
14 directly adopted by others in the field to rapidly discover anti-biofilm chemistries, synthesized
15 using solution- or all-dry method, which are highly effective under different bacteria growth
16 conditions.

17 **2. Methodologies**

18 The capability of a general ML to learn fundamental polymer chemistry-biofilm relationships from
19 numerous and diverse examples is vital to achieving robust predictive performance across polymer
20 synthesis methods and types of interfaces at which biofilm forms. General ML models are
21 characterized by their capability to learn ‘deeper’ patterns concealed in the high-dimensional
22 feature space with proper abstraction and generalization (e.g., dimension reduction) and
23 subsequently apply such learning to achieve accurate predictions of material properties even when
24 new examples appear different from the original training domain. In this work, we pooled together
25 2,240 polymers and their fluorescence intensities against *Pseudomonas aeruginosa* (PAO1)
26 (labeled as F_{PA}) from seven microarrays, including the dataset previously published by Hook et
27 al.^[6,22] as well as unpublished samples from the same lab. Instead of emphasizing the model’s
28 generalization at a range of pathogens similar to previous studies,^[6,30] we aim to investigate a
29 model’s ability to generalize with data obtained from independent experimental sources and
30 possible transferability of learned patterns to a distinct polymerization strategy. Thus, fluorescence
31 intensities against PAO1 are the only model learning target included in the polymer library. This

1 library included homo- and co-polymers with a broad range of pendant groups, including
 2 hydrophilic, hydrophobic, aromatic, cyclic, and branched functional groups. There was an
 3 emphasis on copolymers with weakly amphiphilic pendant groups that were a part of the class of
 4 poly(meth)acrylates previously shown to prevent bacterial biofilm formation.^[31] The polymer
 5 synthesis procedure and biofilm formation measurement are illustrated in “Experimental Data
 6 Collection” of **Figure 1**. Also, the corresponding details are described in Experimental Section.
 7 We cannot exclude that specific copolymer architectures were generated on the microarray as a
 8 result of the polymerization strategy used that would limit the ability to maintain the biological
 9 properties measured on the microdots upon scale-up. However, this is unlikely to be a dominant
 10 effect, as materials selected from the microarray have been successfully scaled up whilst
 11 maintaining antibiofilm properties using a range of polymerization strategies.^[22,32]



12
 13 **Figure 1. Machine Learning Model Development Pipeline.** This pipeline is divided into five
 14 sections with a color code. Referenced figures are indicated correspondingly. During
 15 “Experimental Data Collection” (red frame), a polymer that contained component A and B was
 16 achieved by dispensing x (volume fraction) of monomer A and (1-x) of B in a mixture onto glass
 17 slides to form microarrays. Upon incubation of microarrays with PA01 for 72 hours, the
 18 microarrays’ fluorescence intensities were measured to quantify the biofilm formation on 2,240
 19 polymers (after removing the data below the limit of detection) The impact of applying a limit of
 20 detection on the dataset has been described previously.^[22] With the experimental data,
 21 “Computational Dataset Construction” (blue frame) was performed with molecular descriptors

1 (e.g., Gasteiger partial charges, octanol/water partition coefficient, and other 95 descriptors) and
2 1,024 extended-connectivity fingerprints with a linear summation of two corresponding monomer
3 components' features for every copolymer's computational feature entry against its experimental
4 antibiofilm performance. In "Model Development" (gray blocks), we preprocessed the training set
5 followed by hyperparameter optimizations of support vector regressors. Subsequently, we
6 generated an ensemble model that was trained under various autoencoder-encoded feature sets for
7 the internal model validation (e.g., at the solid-liquid interfaces) with the hold-out test set and
8 previously observed AP. In "Virtual Screening" (yellow blocks), the ensemble model virtually
9 screened a newly built AP dataset for antibiofilm performance with ranked candidates. Among the
10 top-ranked candidates, compositional optimization was performed using the ensemble model.
11 Finally, in "External Model Validation" (green blocks), we synthesized the model-predicted AP
12 using iCVD and tested their antibiofilm performance at liquid-solid and triple interfaces.

13

14 Due to the structural complexity of the pooled polymers, we computed each polymer's features
15 with a linear combination of two corresponding monomer components' features used for this
16 polymer. Therefore, the following steps were carried out: (i) we converted 137 unique monomers
17 (used to derive all polymers) into their corresponding simplified molecular-input line-entry
18 (SMILE) strings for generating computational features. These features include Gasteiger partial
19 charges, octanol/water partition coefficient, and other 95 descriptors, as well as 1,024 extended-
20 connectivity fingerprints^[33] with RDKit. (ii) we linearly combined these monomers' features
21 pairwise to derive all polymers' features. The dataset's structure is presented in "Computational
22 Dataset Construction" in **Figure 1**.

23 Previously, the Bayesian neural network has learned from a polymer microarray comprising 404
24 unique homo- and co-polymers derived from 22 monomers.^[23] We expanded the number of
25 individual monomers included in training from the existing record by six-fold (from 22 to 137),
26 unique molecular fingerprints by more than two-fold (from 183 to 423), and unique homopolymers
27 and copolymers by more than five-fold (from 404 to 2,240).^[23] This considerable expansion in the
28 size and diversity of the training set could bring the following potential challenges to the
29 development of a general model: (i) microarray results obtained from multiple independently
30 performed experiments could introduce variables that were not explicitly controlled (e.g., slight


1 differences in experimenter’s operation); (ii) diversity in monomer chemistry could make accurate
2 prediction more difficult, as unbalanced sample distribution might be embedded into this dataset.
3 To tackle these challenges, a generalizable algorithm was desired. Therefore, we decided to build
4 a radial-basis-function-kernelized support vector regression (SVR) model, which is presumably
5 more generalizable due to its ϵ -insensitive region.^[34]

6 Therefore, we aim to (i) train an SVR ensemble model generalized enough to predict the
7 antibiofilm performances of unseen copolymers comprising diverse monomer chemistries and
8 compositions, making use of the bacterial attachment dataset obtained through high-throughput
9 microarray experimentation carried out at the solid-liquid interface (“Model Development” in
10 Figure 1); (ii) apply this trained ensemble model to virtually screen new hydrophilic-hydrophobic
11 monomer pairs for top-ranked amphiphilic copolymers based on their predicted performance and
12 optimize the hydrophilic-to-hydrophobic ratio of selected comonomer pairs (“Virtual Screening”
13 in Figure 1); (iii) test model transferability across synthetic methods by using iCVD-synthesized
14 AP and transferability across interfacial environments for biofilm formation by predicting biofilms
15 formed on AP at solid-liquid-gas interfaces using a model trained at solid-liquid interfaces
16 (“External Model Validation” in Figure 1). In particular, we categorize model validations at the
17 solid-liquid interfaces as the internal validation and the solid-liquid-gas interface as the external
18 validation. Also, we focus on each of the last three sections sequentially in the rest of the paper.

19 **3. Model Development and Internal Model Validation at the Solid-Liquid Interface**

20 Upon completing the computational dataset construction for the polymers, we performed data
21 preprocessing and hyperparameter optimization. Besides the details mentioned in Experimental
22 Section (e.g., the training-test set split, feature rescaling, etc.), some critical components taken to
23 validate the ensemble model internally are highlighted here. (i) In **Figure 2A**, log-transformation
24 was applied to the fluorescence intensity distribution (labeled as $\text{Log}(F_{PA})$) due to the left-skewed
25 issue in the original distribution. (ii) Three identical autoencoders were trained at each number of
26 reduced features with the signature architecture (**Figure 2B**) to tackle the instabilities caused by
27 the autoencoders’ local optima and the number of reduced features. (iii) To trade off the bias and
28 variance issue, the range of reduced features (e.g., between 45-49) was selected, as shown in
29 **Figure 2C**. The ensemble model consisted of separately trained 15 SVR models, which were
30 developed corresponding to three autoencoders times five reduced feature numbers.

1



2

3 **Figure 2. Key Components of Model Development.** A. The distribution of the experimentally
 4 measured fluorescence intensities after logarithmic transformation. B. Architecture of the three-
 5 layer autoencoder, where the number of nodes in the input and output layers is equal to the original
 6 feature dimensions ($N=1,121$). The code layer has M nodes (equal to the desired number of
 7 reduced features) chosen based on a bias-variance tradeoff in five-fold cross-validation over the
 8 autoencoder-encoded training set. C. A variance-bias tradeoff plot indicated an acceptable range
 9 for the number of reduced features (45-49) for balancing the variance and bias issue. D. The
 10 ensemble model's internal validation over the holdout test set. In each hyperparameter
 11 optimization step over the autoencoder-coded training set, the model was assessed through the
 12 averaged root mean squared error (RMSE), the averaged coefficient of determination (R^2), and
 13 their standard deviations as the evaluation metrics with the five-fold cross-validation (CV). To

1 demonstrate the results of the bias-variance tradeoff in the five-fold CV, Table 1 presents a typical
 2 model benchmark, using 47 reduced features and one of the three autoencoders as an example. The
 3 difference between the averaged RMSE in the 80% training, and validation sets fell within the
 4 desired range (e.g., $\sim 0.03 \text{ Log}(F_{\text{PA}})$) to minimize the variance issue while maintaining acceptable
 5 errors in both sets. For instance, this model could cause up to 5% to 7% errors when predicting a
 6 polymer’s antibiofilm performance with an average $\text{Log}(F_{\text{PA}})$ (~ 6.0) in the collected dataset.
 7 Although this model showed a lower R^2 compared to the previous model’s benchmark (e.g., $R^2 >$
 8 0.85),^[23] we hypothesized that our model could perform better over the polymers out of the training
 9 domain since it was developed over a much more diverse training space as stated earlier.

10 Table 1: Benchmark of Five-Fold CV (\pm standard deviation)

Metrics	Benchmark
Average RMSE for 80% training [$\text{Log}(F_{\text{PA}})$]	0.3611 (± 0.0069)
Average R^2 for 80 % training	0.6467 (± 0.0110)
Average RMSE for Validation [$\text{Log}(F_{\text{PA}})$]	0.3915 (± 0.0273)
Average R^2 for Validation	0.5826 (± 0.0448)

11
 12 Upon confirming the bias-variance tradeoff in each model’s five-fold CV benchmark, we validated
 13 the ensemble model over the holdout test set, namely the first internal validation. These results, as
 14 shown in Table 2, are very comparable to the individual model’s benchmark in the five-fold CV,
 15 which demonstrated the necessity of applying five-fold to foresee the model’s performance over
 16 the holdout test data. In **Figure 2D**, an encouraging agreement between the measured and predicted
 17 quantities is showing in the training $\text{Log}(F_{\text{PA}})$ range. However, errors appear over the ranges (e.g.,
 18 approaching both ends of the training range) with lack of training samples more significantly
 19 compared to the sample-rich range. Thus, we shall be cautious of applying this model to predict a
 20 polymer with extreme $\text{Log}(F_{\text{PA}})$.

21
 22
 23

1 Table 2: Benchmark of Ensemble Model

Metrics	Benchmark
RMSE for Training [$\text{Log}(F_{\text{PA}})$]	0.3567
R^2 for Training	0.6553
RMSE for Holdout Test [$\text{Log}(F_{\text{PA}})$]	0.3835
R^2 for Holdout Test	0.5959

2


3 Upon passing the first internal model validation using the holdout test set, we retrained the
 4 ensemble model with all accessible data to expand its knowledge base and predict other unseen
 5 datasets in later model validations. Here, we report that the ensemble model over the entire dataset
 6 has RMSE and R^2 of 0.3504 $\text{Log}(F_{\text{PA}})$ and 0.6664, respectively.

7 A second internal model validation was performed using the above ensemble model and a
 8 previously reported dataset that measures biofilm formation on AP at the solid-liquid interface.^[22]

9 We first defined AP as a copolymer comprising a hydrophobic monomer (with an octanol/water
 10 partition coefficient, $\text{Log } P > 2$) and a hydrophilic monomer (with $\text{Log } P < 0$). In the reported
 11 dataset,^[22] one hydrophilic monomer (labeled “A” for consistency with the previous labeling
 12 system) paired with four hydrophobic monomers (labeled “9”, “14”, “11”, “12”) fulfilled this
 13 criterion as shown in **Figure 3A**. The four AP series (i.e., 9A, 14A, 11A, and 12A) each features
 14 six compositions, represented by the volume percentage of A that was 0%, 10%, 15%, 20%, 25%,
 15 and 30%. These AP series were reserved for model validation and thus excluded from the training
 16 dataset, i.e., they represent unseen data to the ensemble model.

17 As shown in **Figures 3B** and **3C**, the ML model successfully predicted the effect of monomer
 18 chemistries on biofilm formation at the solid-liquid interface. The values of $\text{Log}(F_{\text{PA}})$ predicted
 19 by the model (solid lines in **Figure 3B**) matched closely to the experimental values (individual
 20 data points in **Figure 3B**). The prediction benchmarks, i.e., an R^2 value of 0.87 and an RMSE
 21 value of 0.16 $\text{Log}(F_{\text{PA}})$, also pointed to the excellent quality of the model predictions. Moreover,
 22 the model correctly identified the surprising effect of the hydrophilic monomer on biofilm
 23 formation, which increased with an increasing amount of A in the AP. In contrast, conventional
 24 wisdom considers hydrophilicity desirable for antifouling purposes.^[35] Interestingly, the model did

1 not accentuate the fluctuations in $\text{Log}(F_{PA})$ among neighboring compositions, which implied that
 2 the model was generalized based on the structure-activity relationship uncovered from the training
 3 set. Taken together, the validation results presented here indicate that the ML model provides
 4 quantitatively accurate predictions of the effect of monomer hydrophilicity and composition on
 5 biofilm formation at the solid-liquid interface. This capability is at the core of the virtual screening
 6 of high-performing AP using a diverse polymer library, as described below.




7
 8 **Figure 3. Experimental validation of ML-predicted biofilm formation on various AP at the**
 9 **solid-liquid interface.** A. Molecular structures of the hydrophilic and hydrophobic monomers
 10 used in the validation;^[22] B, Comparison of the ML predications (lines) and experimental results
 11 (discrete data points) regarding biofilm formation at different film compositions for the four series
 12 of AP. The dashed and dotted lines represent the ML-predicted $\text{Log}(F_{PA})$ values and the standard
 13 errors, respectively; the discrete data points with error bars represent the experimental mean
 14 $\text{Log}(F_{PA})$ and standard errors, respectively. C, Comparison of the ML predictions (y-axis) and
 15 experimental results (x-axis). The predicted linear line (e.g., R^2 of 0.87) is drew with the red dashed
 16 line, while the gray dashed line is the diagonal line (e.g., $y = x$). The four series of AP have the
 17 same hydrophilic monomer (“A”) and different hydrophobic monomers (“9”, “11”, “12”, or “14”).

1 4. Virtual Screening

2 Upon confirming the prediction accuracy of the ensemble model over the internal unseen dataset,
3 we virtually screened all possible AP derived from the 137 unique monomers with various
4 compositions. We first separated these monomers into the hydrophilic ($\text{Log } P < 0$) and the
5 hydrophobic ($\text{Log } P > 2$) groups, respectively, yielding 61 hydrophobic and five hydrophilic
6 monomers. We subsequently combined one hydrophobic monomer's features with one hydrophilic
7 monomer's features at varying compositions from 10 vol.% to 90 vol.% with an increment of 10
8 vol.%. The increment was chosen to test the ensemble model's ability to differentiate the
9 performance of AP within a relatively narrow range of compositions, while maintaining a low
10 computational cost. This choice was unlikely to affect the accuracy of prediction because the
11 experimental uncertainty (e.g., during the quantification of AP composition and biofilm formation)
12 was on the order of 10 vol.%.^[22] Even smaller compositional increments (e.g., 1 vol.% or less) are
13 also compatible the model if needed, albeit a drastic increase in computational cost. Therefore, the
14 entire dataset contained 305 AP series (i.e., 61 hydrophobic monomers \times 5 hydrophilic monomers)
15 and each AP series included nine compositions with the same combination of hydrophobic-
16 hydrophilic monomers.

17 We applied the ensemble model to virtually screen the 50 vol.% AP first, anticipating that to be a
18 top-ranked composition (after preprocessing using the recallable scaler and corresponding
19 autoencoders). As a result, the ensemble model predicted that poly(2-hydroxyethyl methacrylate-
20 *co*-hexafluorobutyl acrylate) with 50 vol. % HEMA (abbreviated as pHEMA-*co*-HFBA, **Figure**
21 **4A**) would result in antibiofilm performance that ranks among the top 5% out of the 305 AP
22 candidates. This monomer pair was selected for the external validation detailed below also because
23 of their appropriate volatility required for iCVD.^[36] We then performed virtual compositional
24 optimization of pHEMA-*co*-HFBA. The predicted $\text{Log}(F_{PA})$ -composition correlation appeared to
25 depend on autoencoder seed selection, with an example shown in **Figure 4B** for 45 reduced
26 features, as well as the number of reduced features, as shown in **Figure 4C**. These observations
27 further supported the need for the ensemble model and our approach of constructing the model to
28 improve stability and generalizability. The model predicted that optimum composition of pHEMA-
29 *co*-HFBA for anti-biofilm-formation lied in the range of 60-80 vol.% HEMA. Note that this
30 prediction was made based on training using bacterial quantification data measured at the solid-
31 liquid interfaces from polymer microarray samples.



1
 2 **Figure 4. Virtual screening results of the best-performing AP and its antibiofilm**
 3 **performances at various compositions.** A. The ensemble model predicted that poly(2-
 4 hydroxyethyl methacrylate-*co*-hexafluorobutyl acrylate) (or pHEMA-*co*-HFBA) was a top
 5 performer, with an antibiofilm performance among the top 5% out of the 305 AP candidates
 6 screened. B. The prediction of antibiofilm performance depends on the autoencoder seeds used for
 7 the SVR models. The thick line represents the averaged prediction for the three seeds tested. C.
 8 The prediction of antibiofilm performance depends on the number of reduced features. The thick
 9 purple line shows the ensemble model prediction, and the colored thin lines represent the model
 10 predictions using different numbers of reduced features (averaged over three SVR models).
 11 Therefore, the ensemble model improves stability and generalizability of the predictions.

12 5. External Model Validation at the Solid-Liquid-Air Interface

13 5.1. iCVD synthesis of AP

14 The ability to combine the virtual screening of AP using a generalized ML model with the high-
 15 fidelity synthesis of AP coatings using iCVD would considerably accelerate the discovery of high-
 16 performing AP in various antibiofilm contexts. Further, here we test whether a generalized ML

1 model that performs well at its native solid-liquid interfaces can also provide useful synthesis
2 guides at unseen solid-liquid-air interfaces.

3 To this end, we synthesized the pHEMA-*co*-HFBA copolymer thin films with vol.% of HEMA
4 ranging from 0% (i.e., pHFBA) to 100% (i.e., pHEMA) using iCVD (see Table S1 for iCVD
5 synthesis conditions). iCVD is an all-dry deposition technique that produces polymer thin films
6 via free radical polymerization^[20,24] in which initiator and monomer(s) are introduced
7 simultaneously into a reaction chamber, as depicted in **Figure 5A**. Due to the solubility of pHEMA
8 homopolymer in an aqueous environment, we introduced a small amount (~15% in final
9 composition) of a hydrophilic crosslinker, namely ethylene glycol dimethacrylate (EGDMA), to
10 improve its stability during biofilm formation tests. The choice of EGDMA as the crosslinker was
11 based on its molecular structure, which resembles that of HEMA. The inclusion of EGDMA
12 rendered the copolymers insoluble during prolonged exposure to an aqueous environment (Figure
13 S6). The introduction of EGDMA to hydrophilic polymer coatings has been shown to have
14 minimal effect on the antifouling activity of the coatings in previous studies. The successful
15 synthesis of pHEMA-*co*-HFBA thin films at various compositions and the pHEMA-*co*-EGDMA
16 thin film was confirmed by Fourier transform infrared spectroscopy (FTIR, **Figure S1**) and X-ray
17 Photoelectron Spectroscopy (XPS, **Table S2**).

18 Complete polymerization for all polymers was confirmed by the absence of the C=C peak at
19 around 1640 cm⁻¹. There was a slight shift in the peak position of C=O, i.e., from 1757 cm⁻¹ (for
20 pHFBA) to 1753 cm⁻¹ (for pHEMA-*co*-HFBA), confirming successful copolymerization reaction
21 rather than physical mixing of the homopolymers.^[37] The composition of pHEMA-*co*-EGDMA
22 was determined using a previously established method.^[38] The composition of pHEMA-*co*-HFBA
23 was calculated by performing peak deconvolution on the C=O group: 1753 cm⁻¹ for HFBA and
24 1728 cm⁻¹ for HEMA. Note that pHEMA-*co*-HFBA with 76 vol.% HEMA was soluble in water
25 (**Figure S2**) and thus not suitable for the antibiofilm experimentation. To further confirm the
26 chemical composition of pHEMA-*co*-HFBA, XPS survey scans were collected, and the
27 composition was calculated and shown in **Table S2**. The difference between the compositions
28 calculated using XPS and that using FTIR was up to 5%. This discrepancy, though relatively
29 small, might suggest possible differences between the film surface and bulk compositions. We
30 chose to use the FTIR results in the compositional analysis of the iCVD-synthesized AP films

1 because they represent the film bulk composition (as the data were collected based on IR signals
2 that penetrated the entire thickness of the films). Whereas XPS is known to be a surface-sensitive
3 technique, probing the composition within very top layer (~10 nm) of a given sample,^[39] and is
4 thus sensitive to surface contamination (e.g., adventitious carbon). Surface chain reorientation
5 (e.g., with hydrophobic moieties concentrated in the top layer) has been reported in AP
6 copolymers,^[12] which may lead to an overestimate of the hydrophobic content when XPS results
7 were used (as shown in Table S2). Furthermore, the ML model was trained on microarray polymer
8 libraries within which copolymer compositions were calculated using the volume ratios of the
9 constituent monomer feeds, which were more characteristic of average bulk compositions than
10 surface compositions. For this reason, the bulk compositions derived from FTIR should provide a
11 closer match with the compositional descriptor used in the training data and hence were expected
12 to be more suited for testing the ML model with respect to the iCVD-synthesized AP coatings. To
13 further minimize possible errors due to differences in compositional units, AP compositions were
14 shown in vol.% (rather than mol.%) to be consistent with training (see Experimental Section).

15 Molecular-scale heterogeneity is one of the key attributes that underpin the antibiofilm
16 performance of AP. To confirm that the pHEMA-*co*-HFBA synthesized using iCVD was indeed
17 free of microphase separation, we performed Fineman-Ross copolymerization analysis (**Figure**
18 **S3**) to determine reactivity ratios of HEMA (r_{HEMA}) and HFBA (r_{HFBA}), respectively (see the
19 experimental section for details). r_{HEMA} and r_{HFBA} were determined to be 1.05 ($R^2 = 0.97$) and 0.65
20 ($R^2 = 0.97$), i.e., $r_{\text{HEMA}} > 1$ and $0 < r_{\text{HEMA}} \cdot r_{\text{HFBA}} < 1$, indicating pHEMA-*co*-HFBA exhibited
21 random copolymerization with a small preference for HEMA addition to a growing chain end.
22 Fineman-Ross plots using XPS-derived HEMA compositions yielded poorer linearity (**Figure S4**
23 and **S5**), which was likely caused by XPS being a surface analysis technique. Hence, iCVD enabled
24 the synthesis of random AP, which is not possible in solution-phase free radical polymerization
25 where AP tend to derive from block copolymers with microphase separation.^[40]

26 Lastly, to confirm the stability of pHEMA-*co*-HFBA, the as-synthesized thin films were
27 immersed in deionized (DI) water over a period of 24 hours at room temperature. The film
28 thickness was measured before and after the incubation (**Figure S6**), which showed decreases less
29 than 10% for pHEMA-*co*-HFBA thin films, and less than 17% for pHEMA-*co*-EGDMA, which
30 were within the range anticipated due to chain reorganization and compression. We further


1 corroborated that attribution through the measurement of refractive index (RI) before and after 24
2 hours of incubation in water (Table S3), as RI is known to reflect the packing density (free volume)
3 of a polymer.^[41] After the 24-hour incubation, we observed an increase in the film RI, implying
4 that the films became more compact with less free volume and a greater density. Furthermore, a
5 previous study has shown that with polymer chain dissolution or coating delamination, iCVD films
6 would disappear in 10 hours.^[42] As such, we believe the observed reduction in thickness after
7 soaking was likely due to chain reorganization and compression.

8 5.2. Performance comparison between model prediction and iCVD-enabled AP thin films

9 The amount of biofilms formed on each iCVD thin film, at solid-liquid-air triple interfaces, was
10 quantified using a crystal violet biofilm assay, following the steps shown in **Figure 5B**. The triple
11 interface was chosen as the focus of our performance testing because biofilms of motile bacteria,
12 including PAO1, form predominantly at the triple interfaces.^[12] Despite the prevalence and the
13 importance of biofilms formed at the triple interface in materials-associated nosocomial infections,
14 antibiofilm performance at the triple interface is not well understood. As such, this focus provides
15 important insight into the materials design principles, while allowing us to explore the
16 transferability of the generalized model that was trained using biofilm data collected at the solid-
17 liquid interfaces to predicting performance at the practically important triple interface.

18 The ensemble model successfully predicted the existence of a minimum in the experimentally
19 obtained biofilm quantities, which resided between 60 and 80 vol.% HEMA (**Figure 5C**). Here,
20 we performed max-min standardization on the $\text{Log}(F_{\text{PA}})$ predicted by the ensemble model (see
21 Eq. (4)) such that the maximum and minimum of the ML predicted means match those of the
22 experimentally acquired means at the triple interface. The experimental means of the amounts of
23 biofilm formed on pHEMA-*co*-HFBA at the triple interface, as indicated by $\text{Log}(A_{\text{norm}}^*)$, traced
24 the trend predicted by the ML model reasonably well, except for that of the hydrophobic pHFBA
25 homopolymer. Specifically, the ML model predicted the hydrophobic homopolymer pHFBA to be
26 more antibiofilm than the hydrophilic homopolymer pHEMA, whereas the biofilms formed at the
27 triple interface demonstrated no significant difference between pHFBA and pHEMA. That
28 discrepancy could be attributed to the high sensitivity of the performance of hydrophobic pHFBA
29 to the presence of an air phase at the interface of interest. Indeed, we demonstrated experimentally
30 that the biofilms formed on the pHFBA at the liquid-solid interface exhibited a mean value of

1 $\text{Log}(A_{\text{norm}}^*)$ close to that predicted by the ML model ($p = 0.34$, **Figure 5D**). That sensitivity of
2 the hydrophobic homopolymer to the presence of an air phase is likely a result of the disparate
3 antifouling mechanisms at play at the different interfaces. For example, air entrapment by a
4 hydrophobic surface has been considered as an effective antifouling mechanism at the liquid-solid
5 interface,^[43] which may lose its effectiveness due to the rapid air exchange at the triple contact
6 line. In summary, the ML model trained using the biofilm data at the solid-liquid interface
7 successfully captured the dependence of AP's antibiofilm performance on the polymer
8 composition. Nevertheless, transfer of the ML model to the triple interface should be carried out
9 with caution, especially in the case of hydrophobic homopolymers.



1
 2 **Figure 5. Model validation at using iCVD-synthesized AP for their antibiofilm performance**
 3 **at the triple interface.** A. A schematic of the iCVD synthesis, during which polymerization occurs
 4 on a substrate placed on a continuously cooled stage. B. Quantification of the amount of biofilms

1 formed at the triple interface on a series of pHEMA-*co*-HFBA with varying compositions. C.
2 Comparison of ML-predicted and experimentally obtained biofilm quantities on the AP series. The
3 solid purple line represents the averaged predictions by the ensemble model trained using data
4 obtained at the solid-liquid (SL) interface and dashed purple lines represent 95% confidence
5 intervals (CI); the red dashes and grey circles represent the experimentally obtained means and
6 individual data points, respectively. D. On the hydrophobic homopolymer pHFBA, although the
7 amounts of biofilms formed at the triple interface (red and “triple”) differed from the ML
8 prediction (purple), that formed at the SL interface (red and “SL”) was consistent with the ML
9 predictions. Error bars represent 95%CI. *** indicates $p < 0.001$, ** $p < 0.01$, * $p < 0.05$, and ns
10 $p > 0.05$.

11 **6. Discussion and Conclusion**

12 In this study, we constructed and applied an ensemble model to achieve high-throughput screening
13 of a large virtual library of AP to search for antibiofilm polymer chemistries in the vast chemical
14 and compositional space. The model provided accurate predictions of antibiofilm performance of
15 AP synthesized using a precision synthesis approach, i.e., iCVD, based on training datasets
16 obtained using a high-throughput approach, i.e., microarrays. It predicted the quantity of solid-
17 liquid biofilms reasonably well ($R^2=0.60$, $RMSE=0.38 \text{ Log}(F_{PA})$) involving polymers over a vast
18 chemistry-composition design space. Intriguingly, the accuracy of the model improved further
19 ($R^2=0.87$, $RMSE=0.16 \text{ Log}(F_{PA})$) when tested on the hold-out set comprising only AP. This is
20 quite encouraging because the model successfully extrapolated the behavior of AP from a training
21 set without any examples of amphiphilic copolymers. Moreover, the prediction accuracy AP even
22 surpassed that obtained during training for all copolymers ($R^2=0.66$, $RMSE=0.36 \text{ Log}(F_{PA})$) by
23 an appreciable margin. One possible explanation might be that polymers in the training set featured
24 disparate antifouling mechanisms (or QSAR), which the model captured with varying degrees of
25 success, and that the QSAR for AP might belong to the category that the model captured to a
26 greater degree.

27 Furthermore, for biofilms formed at the air-liquid-solid triple interface, the ensemble model
28 successfully predicted how antibiofilm performance varies with the polymer composition,
29 identifying an optimum at the HEMA composition of 60-80 vol%, which was consistent with the
30 experimental results. As such, we demonstrated the ensemble model as a reliable tool for virtual

1 screening of high-performance amphiphilic chemistries and for optimizing their compositional
2 design. The model also points to the possibility of transferring the knowledge obtained from
3 biofilm data obtained under one condition (i.e., liquid-solid interface) to identify best-performing
4 AP under other conditions (e.g., the triple interface), and more broadly, the generalizability of the
5 ensemble model demonstrated here.

6 That generalizability was enabled by the robust model development framework we established for
7 generating ML models with reasonable bias-variance tradeoff and generalizability. The model was
8 achieved through the implementation of rigorous data-preprocessing steps (e.g., log-
9 transformation, feature rescaling, and dimensionality reduction with autoencoders), of
10 hyperparameter optimization in a five-fold CV, and of an ensemble model. The model
11 demonstrated the ability to capture broad diversity in monomer chemistry (137) and unique
12 molecular fingerprints (423), with a modest abundance of samples during training (2,240).
13 Additionally, its ability to tackle diverse training datasets, pooled from seven independent
14 experiments, greatly alleviated the common challenge of data scarcity for training ML models in
15 antifouling material studies. That flexibility in training dataset sources also unveiled the tantalizing
16 potential of continual expansion and enrichment of the training dataset via extensive inter-
17 laboratory collaborations, akin to the Human Genome Project.

18 We employed the approach of SVR assisted by autoencoders, as other methods attempted (e.g.,
19 neural nets) caused significant bias issues. Despite the challenges around model interpretability,
20 this approach demonstrated distinct advantages in this study, such as a lower time complexity (e.g.,
21 compared to feature selection) in handling the size of the datasets in this study, which was a result
22 of the SVR's capability to combine dimensionality reduction and implicit mapping. Furthermore,
23 model interpretation can be achieved by identifying clusters with reduced feature vectors
24 (computed by autoencoders) or other unsupervised mapping strategies to extract the key functional
25 moieties that determine the antibiofilm performance. Compared with the state of the art, ^[6,22,23],
26 the ensemble model reported here is uniquely able to address a broad polymer design space due to
27 the unprecedentedly diverse training dataset employed in this work. Nevertheless, it could be
28 outperformed in terms of prediction errors by models trained to operate within a confined domain
29 of chemistry. Our future work will focus on improving the computational method for copolymer
30 feature generation as the current approach of linear combination may have limited the SVR

1 mapping ability. We will also expand the design space by incorporating ionizable functional
2 groups, such that the model can predict the performance of a wider variety of AP (e.g., zwitterionic
3 hydrophilic groups). We will improve the accuracy of model predictions by broadly sampling a
4 variety of ML approaches, such as transfer learning while retraining the general model building
5 framework reported here to address the fundamental distinctions among disparate antifouling
6 mechanisms.

7 **7. Experimental Section**

8 **Collection of bacterial microarray data**

9 The synthesis procedure and biofilm formation measurement are followed the methods previously
10 described.^[6,22] Polymers on microarrays were derived from various monomers mixed pairwise at
11 different compositions and incubated with PAO1 for 72 hours in RPMI-1640 media. Plasmids for
12 constitutively expressing fluorescent proteins GFP (pBK-miniTn7-egfp) and mCherry (pMMR)
13 were introduced into the relevant host strain by conjugation or electroporation to enable bacterial
14 quantification.

15 **Additional details of model development**

16 Upon completing the computational dataset construction for the polymers, we performed data-
17 preprocessing to clean the data and reduce its redundancy. Out of the 2,420 polymers, 180
18 polymers had a fluorescence intensity below the limit of detection (LOD) (e.g., these fluorescence
19 intensities were labeled as “zero”, which did not reflect the actual anti-biofilm performances) and
20 were thus removed from the dataset to prevent them from potentially misleading ML models,
21 leaving 2,240 polymers in the final dataset. Since the original fluorescence intensity distribution
22 was right-skewed (not showing), a logarithmic transformation was applied to all the remaining
23 fluorescence intensity values (F_{PA}), which were labeled as $\text{Log}(F_{PA})$ as shown in **Figure 2A**. We
24 further split the dataset into a training set and a holdout test set at a ratio of 80:20 with stratification
25 due to the relatively small size of the dataset and applied a recallable minimum-maximum scaler
26 to the training set.

27 The autoencoder, with its signature three-layer structure (**Figure 2B**),^[44] was effective in
28 distinguishing all polymers in the training space while reducing the noise and redundancy in the
29 dataset. We constructed the autoencoder to reduce the training set’s dimension (labeled as the
30 encoded training set) with proper reference validation assisted by TensorFlow and Keras. Despite

1 the effectiveness of the autoencoder, there remains two sources for instabilities. First, an optimized
2 autoencoder was unlikely to behave consistently once a completely new seed was used due to its
3 nonconvexity (e.g., different local optimums would lead to different reduced feature contents).
4 Additionally, the number of reduced features used could bring about variability in the final model
5 predictions. To account for those instabilities, we developed an ensemble model by averaging the
6 predictions of three autoencoders, which have similar mean squared error but a different number
7 of reduced features. The ensemble method has been shown to simultaneously mitigate variance
8 and bias issues, therefore improving the model’s generalizability and performance.^[45]

9 Hyperparameter optimization is also another key to balancing the bias and variance tradeoff.
10 Building upon the strengths of SVR, e.g., its generalizability and low time-complexity by implicit
11 mapping,^[34] we developed a radial-basis-function-kernelized SVR model using the encoded
12 training set.

13 To achieve a reasonable bias-variance trade-off we investigated the model’s performance ranging
14 from ten to one hundred reduced features with an increment of ten as shown in **Figure 2C**. Under
15 each reduced dimension, an SVR model’s hyperparameters were optimized by the random search
16 algorithm in CV. We also assessed the averaged root mean squared error (RMSE), the averaged
17 coefficient of determination (R^2), and their standard deviations as the evaluation metrics for every
18 model’s optimization process.

19 To the best of our knowledge, there is not a quantitative method widely accepted in the field of
20 ML that allows non-arbitrary selection of the number of the reduced features. Optimization of such
21 selection is of high theoretical and practical importance but is beyond the scope of this work.
22 Therefore, we took the following qualitative approach to define an acceptable range for the number
23 of reduced features. As shown in **Figure 2C**, when the number of reduced features was too small
24 (e.g., 10), the models performed poorly as indicated by the high average RMSE during training
25 (blue curve) and validation (red curve), despite a relatively narrow difference between these two
26 sets (e.g., 0.013 RMSE difference in terms of $\text{Log}(F_{PA})$ when ten reduced features were applied),
27 which is typical of a bias issue – i.e., not enough fitting dimensions to capture the trends contained
28 in the training (or validation) set. In contrast, when the number of reduced features was too high
29 (e.g., 70 and higher), the model performance started to diverge considerably between the two sets
30 (e.g., 0.035 RMSE difference in terms of $\text{Log}(F_{PA})$ when 70 reduced features were applied). That

1 gap between validation and training indicated a variance issue, suggesting that the models were
2 not general enough to make accurate predictions for previously unseen polymer chemistries.

3 The ability to generalize would be essential for the purpose of virtual screening of novel AP for
4 their antibiofilm performance. Therefore, to trade off the bias-variance issue, we identified an
5 acceptable range for the number of reduced features to be between 45 to 49 in this study. To
6 minimize potential variation in model prediction due to the selection of a single reduced feature
7 number, we averaged the predictions generated by models developed using each of the five
8 reduced feature numbers from 45 to 49. In total, this ensemble model consisted 15 individually
9 train SVR models. It should also be noted that the reproducibility of the model can be guaranteed
10 by using the same seeds for the initialization of autoencoder neural networks.

11 Vapor-deposition of AP

12 The amphiphilic copolymer thin films were synthesized using an all-dry deposition technique
13 termed *initiated* chemical vapor deposition (iCVD). The iCVD mechanism involves free radical
14 polymerization,^[26] in which initiator and monomer(s) are introduced simultaneously into a reaction
15 chamber, as depicted in **Figure 5A**. In this chamber, the heated filament wires are suspended above
16 a continuously cooled substrate (i.e., silicon [Si] wafer and glass coverslips) and promote thermal
17 decomposition of the initiator resulting in free radicals. Then, these radicals chemisorb to adsorbed
18 monomers on the substrate via the Eley-Rideal mechanism^[25,46] so that polymerization is initiated,
19 and monomer mono/multilayers are formed.

20 Before iCVD deposition, the coverslips and Si wafer were cleaned in a plasma cleaner (PDC-001-
21 HP, Harrick Plasma) for 2 minutes at a high radio frequency (RF) setting. No covalent grafting
22 was required to achieve sufficient adhesion of the polymer thin films to the underlying substrates
23 used in this study (Figure S6).^[13,47,48] The substrate-independent nature of the iCVD technology
24 and good adhesion of the iCVD coatings on most substrates have been well documented.^[29,36,49]
25 That adhesion was enabled by the strong molecular interactions between the iCVD polymer and
26 the underlying substrate, due to the strong molecular adsorption of monomer precursors to the
27 substrate during the iCVD synthesis process (which has been described using the Brunauer–
28 Emmett–Teller theory). Subsequently, pHEMA-*co*-HFBA copolymer thin films were
29 synthesized using a customer-built iCVD reactor (335 mm diameter, 50 mm height), which was
30 evacuated by an E2M40 rotary vane vacuum pump (Edwards Vacuum, UK). pHEMA-*co*-HFBA

1 amphiphilic copolymer thin films with different compositions were achieved by varying HFBA
2 and HEMA flow rates, respectively. The deposition conditions are summarized in Table S1. The
3 pressure in the reactor chamber was set to 1.1 Torr by a throttling valve (MKS Instruments, USA),
4 and it was maintained by a manometer (Baratron, MKS Instruments, USA). The stage temperature
5 of the chamber was set to 20°C by an Accel 500 LC recirculating chiller (Thermo Fisher, USA),
6 and the filament nickel-chromium wires (80% Ni/20% Cr) were heated to 220-230°C using a DC
7 power source (B&K Precision, USA). A type K thermocouple (Omega Engineering, USA)
8 measured both filament and stage temperatures. *In-situ* laser interferometry (He-Ne laser, JDSU,
9 USA) was located above the reactor glass lid to enable the coating thickness control. During
10 deposition, HFBA was slightly heated to 25°C. To vaporize HEMA, the monomer jar was heated
11 at 75°C. All monomers were metered into the reactor using needle valves (Swagelok, USA). The
12 initiator, TBPO was maintained at room temperature, and its flow rate was set using a mass flow
13 controller (MKS Instruments, USA). Argon (Ar) was utilized as a carrier gas to maintain a constant
14 total gas flow rate at four standard cubic centimeters per minute (sccm) and thus constant residence
15 time for gas flow. Lastly, pHEMA homopolymer was deposited with a trace of ethylene glycol
16 dimethacrylate (EGDMA) at a pressure of 0.2 Torr and a stage temperature of 30 °C. EGDMA
17 was used as a crosslinker to make the PHEMA film insoluble.^[38] EGDMA was chosen due to its
18 molecular resemblance to HEMA.

19 After the vapor deposition, AP coatings were left to equilibrate overnight (~16 hours) under
20 vacuum at 20 °C. This equilibration time was chosen because it allowed ample time for pHEMA
21 to equilibrate (typically over 60-100 min)^[50,51] while avoiding the potential aging effect (typically
22 over months-years).^[52] This also allowed us to match training conditions, where the ML model
23 was trained using material properties and biofilm data obtained on well-equilibrated but still fresh
24 polymer microarrays, thus precluding potential effects of equilibration and aging on the learned
25 properties-biofilm relationships.

26 [Chemical Characterization.](#)

27 Fourier-transform infrared spectroscopy (FTIR) (Bruker Vertex V80V Vacuum FTIR system with
28 cooled MCT detector) was used to determine the final composition of copolymer thin films. The
29 spectra were acquired over 400 - 4000 cm⁻¹ with a resolution of 4 cm⁻¹ and 256 total scans.^[53] The
30 spectra were analyzed, and the baseline was corrected using OPUS software (Bruker). The

1 thickness of the thin films on a flat surface (Si wafers) was measured by variable angle
 2 spectroscopic ellipsometry (J.A. Woollam Alpha-SE ellipsometer) at three different angles (65°,
 3 70°, and 75°) with a wavelength range from 315 to 718 nm.^[54] The optical model with a Cauchy
 4 function was used to fit-in experimental data that consisted of 3 different layers: silicon wafer (Si)
 5 as a substrate, silicon oxide (IV) (SiO₂) as a calibration standard, and the copolymer thin film.

6 X-ray photoelectron spectroscopy (XPS) was performed using a Scienta Omicron ESCA 2SR
 7 (Uppsala, Sweden) with operating pressure of 1×10⁻⁹ Torr. X-rays were generated from
 8 monochromatic Al K α at 300W (15 kV; 20 mA) with an analysis spot size of 2 mm in diameter.
 9 Survey scans were collected to determine the composition of the copolymer thin films.

10 Fineman-Ross

11 To determine the type of copolymerization for pHEMA-co-HFBA, Fineman-Ross
 12 copolymerization analysis was used to determine reactivities of HEMA and HFBA,
 13 respectively.^[55]

14 The surface monomer composition, f_{HEMA} , was calculated as follows:

$$f_{HEMA} = \frac{\frac{P_{HEMA}}{P_{sat,HEMA}}}{\frac{P_{HEMA}}{P_{sat,HEMA}} + \frac{P_{HFBA}}{P_{sat,HFBA}}} \quad (1)$$

15 where $\frac{P_{HEMA}}{P_{sat,HEMA}}$ or $\frac{P_{HFBA}}{P_{sat,HFBA}}$ is monomer partial pressure over monomer saturated pressure, which
 16 is also representative of the monomer surface concentration of each co-monomer.

17 The film composition (F_{HEMA}) was obtained from FTIR as mentioned above. To determine, the
 18 type of copolymerization (either random, block or alternating), Fineman-Ross equation was used
 19 as follows:

$$\frac{f_{HEMA}(1 - 2F_{HEMA})}{F_{HEMA}(1 - f_{HEMA})} = r_{HFBA} + r_{HEMA} \frac{f_{HEMA}^2(F_{HEMA} - 1)}{F_{HEMA}(1 - f_{HEMA})^2} \quad (2)$$

20 where r_{HEMA} and r_{HFBA} are reactivities of HEMA and HFBA, which can be determined from the
 21 slope and intercept, respectively.

1 Biofilm Assay at Solid-Liquid-Air and Solid-Liquid Interfaces

2 After confirming the hydrophilic content in each pHEMA-*co*-HFBA with FTIR, we performed
3 a crystal violet biofilm assay to evaluate biofilm formation as a function of volume percentage
4 of HEMA (vol.% HEMA). The reason for using vol.% is to keep consistent with the
5 quantification method used in the training dataset, which approximates polymer compositions
6 on the microarray slide based on the volume percentage of each monomer feed used for
7 synthesis (assuming complete conversion of comonomers). To convert mol.% into vol.%, we
8 adopted molar volumes of 121.63 mL mol⁻¹ for HEMA^[56] and 185.56 mL mol⁻¹ for HFBA^[57]
9 (see SI for details). The procedures of the crystal violet biofilm assay are reported elsewhere.^[12]
10 Briefly, PAO1 were grown to stationary phase (37 °C, 16 h, 225 rpm) in Luria Bertani (LB,
11 Lennox) broth and subcultured in fresh LB broth (1:100 dilution). For the biofilm assay at solid-
12 liquid-air interfaces, the AP-coated glass substrates with hydrophilic content ranging from 0%
13 to 100%, along with the uncoated controls, were each half-submerged vertically in the diluted
14 LB culture contained the wells of 12-well culture plates. This was followed by static incubation
15 for 8 hours at 37 °C based on *P. aeruginosa* biofilm lifecycle and previous work.^[12,58,59] At this
16 point in time (8 hours) when culture transitions from stage II to III, quantification is most
17 reliable due to the presence of linear and vertical biofilm development; further growth would
18 lead to biofilm maturation, giving rise to a three-dimensional community (stage IV, 14-24h)
19 where biomass accumulation would reflect more of multiplication and quorum sensing,^[60]
20 rather than bacteria-material interactions. For the biofilm assay at solid-liquid interfaces, the
21 hydrophobic pHFBA-coated substrates (i.e., “0% HEMA”), along with the uncoated controls,
22 were placed horizontally with the coated side facing upward on the well bottom of 6-well
23 culture plates. These substrates were fully submerged in 4 mL of the diluted LB culture and
24 incubated with gentle shaking (60 rpm) for 72 h at 37 °C, with replacement of 3.5 mL of the
25 spent medium in each well with fresh LB every 24 h. The shaking and extended incubation
26 time were implemented to encourage biofilm formation by PAO1 at the solid-liquid interfaces.
27 At the end of the incubation period specified for either type of interfaces, the biofilm-covered
28 substrates were rinsed in Milli-Q water to dislodge loosely attached cells, followed by staining
29 in crystal violet solution (0.5% w/v) for 15 min. After removing unbound dye molecules in
30 Milli-Q water, crystal violet molecules bound to the biofilm were dissolved in 1 mL acetic acid
31 (30% v/v). At least four biological replicates were included for each type of substrates. To

1 correct for the artifact caused by crystal violet bound to polymer coatings, medium controls
 2 (LB without bacteria) were included for each substrate type alongside the inoculated samples.
 3 We measured the absorbance of the dissolved crystal violet from each sample at 550 nm and
 4 obtained the normalized absorbance based on the following equation.

$$A_{\text{norm}}^* = \frac{A_{\text{b,P}}^*}{A_{\text{b,G}}^*} = \frac{(A_{\text{t,P}} - A_{\text{0,P}})/\text{OD}_{600,\text{P}}}{(A_{\text{t,G}} - A_{\text{0,G}})/\text{OD}_{600,\text{G}}} \quad (3)$$

5 Where $A_{\text{t,P}}$ and $A_{\text{t,G}}$ are total absorbance for polymer-coated (“P”) and glass coverslip (“G”),
 6 respectively. $A_{\text{0,P}}$ and $A_{\text{0,G}}$ are absorbance measured from bacteria-free controls. Thus, the
 7 difference between these two measured absorbances (e.g., $A_{\text{t,P}} - A_{\text{0,P}}$) is the corrected
 8 absorbance. This value was then divided by its corresponding OD_{600} at the end of the incubation,
 9 which normalizes the biofilm growth by the planktonic cell density to account for variations in
 10 growth conditions, resulting in $A_{\text{b,P}}^*$ and $A_{\text{b,G}}^*$. Lastly, the ratio of $A_{\text{b,P}}^*$ over $A_{\text{b,G}}^*$ is computed,
 11 denoted A_{norm}^* , which benchmarks biofilm formed on the coatings of interest against bare glass
 12 coverslip. A_{norm}^* less than unity suggests the coating outperformed glass in terms of its antibiofilm
 13 property, and vice versa.

14 In order to compare the ML predictions directly with the experimental observations,
 15 standardization of the biomass units was performed. The unit of ML-predicted biomass was
 16 $\text{Log}F_{\text{PA}}$, which was inherited from the fluorescent microarray experiment. Rescaling of the ML-
 17 predicted $\text{Log}F_{\text{PA}}$ values was performed by applying Eq.(4), such that the maxima and minima of
 18 the means predicted by ML were set to align with that of the experimentally observed maxima and
 19 minima, respectively.

$$\text{Std. Log}(F_{\text{PA}}) = \frac{\text{Log}(F_{\text{PA}}) - \min[\text{Log}(F_{\text{PA}})]}{\max[\text{Log}(F_{\text{PA}})] - \min[\text{Log}(F_{\text{PA}})]} \cdot \{\max[\text{Log}(A_{\text{norm}}^*)] - \min[\text{Log}(A_{\text{norm}}^*)]\} + \min[\text{Log}(A_{\text{norm}}^*)] \quad (4)$$

20 Where *Biomass* is the amount of biofilm quantified in either A_{norm}^* or F_{PA} ; “min[]” and “max[]”
 21 are functions that return minima and maxima of the logarithmic mean biomass among all pHEMA-
 22 *co*-HFBA compositions.

1 **Statistical Analysis**

2 Analysis of variance (ANOVA) and post hoc TukeyHSD were performed using statistical
3 programming language R (RStudio, Version 1.2.1335) to compare biofilm formation observed
4 during experiments at solid-liquid-gas and solid-liquid interfaces and that predicted by the ML
5 model, at a 95% confidence level.

6 **Supporting Information**

7 Supporting Information is available from Wiley Online Library or from the author.

8 **Acknowledgments**

9 The authors want to thank the Office of Naval Research (ONR) for support through Award MURI
10 N00014-20-1-2418 to R.Y. and through Award USDA NIFA 2021-67034-35040 to Y.C. The
11 authors also want to acknowledge the Samuel C. Fleming Family Graduate Fellowship for the
12 support granted to A.K. Finally, the authors wish to thank Cornell NanoScale Facility (grant
13 number NNCI-2025233), Cornell Center for Materials Research (grant number DMR-1719875),
14 and Cornell Restricted Access Data Center for providing the facilities required for conducting this
15 research. A.L.H kindly acknowledges the University of Nottingham for funding his Nottingham
16 Research Fellowship. Funding from Wellcome Trust (grant numbers 103882 and 103884) is also
17 kindly acknowledged.

18 **Conflict of Interest**

19 The authors declare no conflict of interest.

1 **References**

- 2 [1] J. W. Costerton, P. S. Stewart, E. P. Greenberg, *Science (1979)* **1999**, 284, 1318.
- 3 [2] A. SMITH, *Adv Drug Deliv Rev* **2005**, 57, 1539.
- 4 [3] H.-C. Flemming, J. Wingender, U. Szewzyk, P. Steinberg, S. A. Rice, S. Kjelleberg, *Nat*
5 *Rev Microbiol* **2016**, 14, 563.
- 6 [4] M. Tyers, G. D. Wright, *Nat Rev Microbiol* **2019**, 17, 141.
- 7 [5] J.-L. Mainardi, R. Villet, T. D. Bugg, C. Mayer, M. Arthur, *FEMS Microbiol Rev* **2008**,
8 32, 386.
- 9 [6] A. L. Hook, C. Chang, J. Yang, S. Atkinson, R. Langer, D. G. Anderson, M. C. Davies, P.
10 Williams, M. R. Alexander, *Advanced Materials* **2013**, 25, 2542.
- 11 [7] E. Ostuni, R. G. Chapman, M. N. Liang, G. Meluleni, G. Pier, D. E. Ingber, G. M.
12 Whitesides, *Langmuir* **2001**, 17, 6336.
- 13 [8] R. Yang, H. Jang, R. Stocker, K. K. Gleason, *Advanced Materials* **2014**, 26, 1711.
- 14 [9] T.-S. Wong, S. H. Kang, S. K. Y. Tang, E. J. Smythe, B. D. Hatton, A. Grinthal, J.
15 Aizenberg, *Nature* **2011**, 477, 443.
- 16 [10] C. S. Gudipati, J. A. Finlay, J. A. Callow, M. E. Callow, K. L. Wooley, *Langmuir* **2005**,
17 21, 3044.
- 18 [11] J.-F. Dubern, A. L. Hook, A. M. Carabelli, C.-Y. Chang, C. A. Lewis-Lloyd, J. C.
19 Lockett, L. Burroughs, A. A. Dundas, D. J. Humes, D. J. Irvine, M. R. Alexander, P.
20 Williams, *Sci Adv* **2023**, 9, DOI 10.1126/sciadv.add7474.
- 21 [12] T. B. Donadt, R. Yang, *Adv Mater Interfaces* **2021**, 8, 2001791.
- 22 [13] A. Khlyustova, M. Kirsch, R. Yang, *ACS Sustain Chem Eng* **2022**, 10, 15699.
- 23 [14] C. A. Amadei, R. Yang, M. Chiesa, K. K. Gleason, S. Santos, *ACS Appl Mater Interfaces*
24 **2014**, 6, 4705.
- 25 [15] R. Yang, E. Goktekin, M. Wang, K. K. Gleason, *J Biomater Sci Polym Ed* **2014**, 25, 1687.
- 26 [16] S. Bhatt, J. Pulpytel, G. Ceccone, P. Lisboa, F. Rossi, V. Kumar, F. Arefi-Khonsari,
27 *Langmuir* **2011**, 27, 14570.
- 28 [17] C. Leng, K. A. Gibney, Y. Liu, G. N. Tew, Z. Chen, *ACS Macro Lett* **2013**, 2, 1011.
- 29 [18] A. v. Dudchenko, P. Bengani-Lutz, A. Asatekin, M. S. Mauter, *ACS Appl Polym Mater*
30 **2020**, 2, 4709.
- 31 [19] S. H. Baxamusa, K. K. Gleason, *Adv Funct Mater* **2009**, 19, 3489.

- 1 [20] Z. Zhao, H. Ni, Z. Han, T. Jiang, Y. Xu, X. Lu, P. Ye, *ACS Appl Mater Interfaces* **2013**, *5*,
2 7808.
- 3 [21] Y. Cheng, R. Yang, *Acc Mater Res* **2021**, *2*, 979.
- 4 [22] A. L. Hook, C.-Y. Chang, J. Yang, J. Luckett, A. Cockayne, S. Atkinson, Y. Mei, R.
5 Bayston, D. J. Irvine, R. Langer, D. G. Anderson, P. Williams, M. C. Davies, M. R.
6 Alexander, *Nat Biotechnol* **2012**, *30*, 868.
- 7 [23] P. Mikulskis, A. Hook, A. A. Dundas, D. Irvine, O. Sanni, D. Anderson, R. Langer, M. R.
8 Alexander, P. Williams, D. A. Winkler, *ACS Appl Mater Interfaces* **2018**, *10*, 139.
- 9 [24] A. Khlyustova, Y. Cheng, R. Yang, *J Mater Chem B* **2020**, *8*, 6588.
- 10 [25] K. K. S. Lau, K. K. Gleason, *Macromolecules* **2006**, *39*, 3688.
- 11 [26] A. M. Coclite, K. K. Gleason, *Plasma Processes and Polymers* **2012**, *9*, 425.
- 12 [27] Y. Cheng, A. Khlyustova, P. Chen, R. Yang, *Macromolecules* **2020**, *53*, 10699.
- 13 [28] K. K. Gleason, *Nature Reviews Physics* **2020**, *2*, 347.
- 14 [29] T. Franklin, R. Yang, *ACS Biomater Sci Eng* **2020**, *6*, 182.
- 15 [30] A. A. Dundas, O. Sanni, J. Dubern, G. Dimitrakakis, A. L. Hook, D. J. Irvine, P. Williams,
16 M. R. Alexander, *Advanced Materials* **2019**, *31*, 1903513.
- 17 [31] O. Sanni, C. Chang, D. G. Anderson, R. Langer, M. C. Davies, P. M. Williams, P.
18 Williams, M. R. Alexander, A. L. Hook, *Adv Healthc Mater* **2015**, *4*, 695.
- 19 [32] K. Adlington, N. T. Nguyen, E. Eaves, J. Yang, C.-Y. Chang, J. Li, A. L. Gower, A.
20 Stimpson, D. G. Anderson, R. Langer, M. C. Davies, A. L. Hook, P. Williams, M. R.
21 Alexander, D. J. Irvine, *Biomacromolecules* **2016**, *17*, 2830.
- 22 [33] D. Rogers, M. Hahn, *J Chem Inf Model* **2010**, *50*, 742.
- 23 [34] H. B. C. J. C. , K. L. S. A. V. V. Drucker, *Adv Neural Inf Process Syst* **1996**, *9*, 155.
- 24 [35] E. Ostuni, R. G. Chapman, R. E. Holmlin, S. Takayama, G. M. Whitesides, *Langmuir*
25 **2001**, *17*, 5605.
- 26 [36] K. K. Gleason, *CVD Polymers: Fabrication of Organic Surfaces and Devices*, Wiley-
27 VCH Verlag GmbH & Co., Weinheim, **2015**.
- 28 [37] A. Liu, E. Goktekin, K. K. Gleason, *Langmuir* **2014**, *30*, 14189.
- 29 [38] W. Reichstein, L. Sommer, S. Veziroglu, S. Sayin, S. Schröder, Y. K. Mishra, E. İ.
30 Saygili, F. Karayürek, Y. Açil, J. Wiltfang, A. Gülses, F. Faupel, O. C. Aktas, *Polymers*
31 *(Basel)* **2021**, *13*, 186.
- 32 [39] J. B. Gilbert, M. F. Rubner, R. E. Cohen, *Proceedings of the National Academy of*
33 *Sciences* **2013**, *110*, 6651.

- 1 [40] A. K. Leonardi, C. K. Ober, *Annu Rev Chem Biomol Eng* **2019**, *10*, 241.
- 2 [41] V. Raghunathan, J. Luis Yagüe, J. Xu, J. Michel, K. KGleason, L. C. Kimerling, H. Ma,
3 A. K. Y Jen, L. R. Dalton, J. M. Lee, D. J. Kim, H. Ahn, S. H. Park, G. Kim, G. H. Kim,
4 O. K. Kwon, K. J. Kim, H. Zhang, X. Jian, X. Han, M. Zhao, G. Morthier, R. Baets, W.
5 Groh, A. Zimmermann, *Fabrication and Design Considerations for Multilevel Active*
6 *Polymeric Devices*, Optical Society Of America, **2002**.
- 7 [42] R. Yang, H. Jang, R. Stocker, K. K. Gleason, *Advanced Materials* **2014**, *26*, 1711.
- 8 [43] Y. Cheng, G. Feng, C. I. Moraru, *Front Microbiol* **2019**, *10*, DOI
9 10.3389/fmicb.2019.00191.
- 10 [44] Y. Wang, H. Yao, S. Zhao, *Neurocomputing* **2016**, *184*, 232.
- 11 [45] C. McGill, M. Forsuelo, Y. Guan, W. H. Green, *J Chem Inf Model* **2021**, *61*, 2594.
- 12 [46] A. Khlyustova, R. Yang, *Front Bioeng Biotechnol* **2021**, *9*, DOI
13 10.3389/fbioe.2021.670541.
- 14 [47] W. E. Tenhaeff, K. K. Gleason, *Adv Funct Mater* **2008**, *18*, 979.
- 15 [48] A. Khlyustova, M. Kirsch, X. Ma, Y. Cheng, R. Yang, *J Mater Chem B* **2022**, *10*, 2728.
- 16 [49] P. Chen, J. Lang, Y. Zhou, A. Khlyustova, Z. Zhang, X. Ma, S. Liu, Y. Cheng, R. Yang,
17 *Sci Adv* **2022**, *8*, DOI 10.1126/sciadv.abl8812.
- 18 [50] C. Esen, R. H. Şenay, E. Feyzioğlu, S. Akgöl, *Journal of Nanoparticle Research* **2014**, *16*,
19 2255.
- 20 [51] N. L. Smith, Z. Hong, S. A. Asher, *Analyst* **2014**, *139*, 6379.
- 21 [52] T. V. Nguyen, X. H. Le, P. H. Dao, C. Decker, P. Nguyen-Tri, *Prog Org Coat* **2018**, *124*,
22 137.
- 23 [53] G. Ozaydin-Ince, J. M. Dubach, K. K. Gleason, H. A. Clark, *Proceedings of the National*
24 *Academy of Sciences* **2011**, *108*, 2656.
- 25 [54] C. D. Petruczok, R. Yang, K. K. Gleason, *Macromolecules* **2013**, *46*, 1832.
- 26 [55] G. Odian, *Principles of Polymerization*, Wiley, **2004**.
- 27 [56] National Center for Biotechnology Information (2023), “PubChem Compound Summary
28 for CID 13360, 2-Hydroxyethyl methacrylate,” can be found under
29 <https://pubchem.ncbi.nlm.nih.gov/compound/2-Hydroxyethyl-methacrylate>, **2023**.
- 30 [57] Sigma-Aldrich, “Sigma-Aldrich Compound Summary for 2,2,3,4,4,4-Hexafluorobutyl
31 methacrylate,” can be found under
32 <https://www.sigmaaldrich.com/US/en/product/aldrich/371971>, **2023**.
- 33 [58] T. Rasamiravaka, Q. Labtani, P. Duez, M. el Jaziri, *Biomed Res Int* **2015**, *2015*, 1.

- 1 [59] C. S. L. Spake, E. M. Berns, L. Sahakian, A. Turcu, A. Clayton, J. Glasser, C. Barrett, D.
- 2 Barber, V. Antoci, C. T. Born, D. R. Garcia, *Journal of Orthopaedic Research* **2022**, *40*,
- 3 2448.
- 4 [60] C. Solano, M. Echeverz, I. Lasa, *Curr Opin Microbiol* **2014**, *18*, 96.
- 5